Molecular Pharmacology Fast Forward. Published on July 1, 2009 as doi:10.1124/mol.109.056986
This article has not been copyedited and formatted. The final version may differ from this version.



# Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b

Sayaka Komagata, Miki Nakajima, Shingo Takagi, Takuya Mohri, Takao Taniya, and Tsuyoshi Yokoi

*Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan (S.K., M.N., S.T., T.M., T.Y.); and Futaba Breast Clinic, Kanazawa, Japan (T.T.)*

Molecular Pharmacology Fast Forward. Published on July 1, 2009 as DOI: 10.1124/mol.109.056986
This article has not been copyedited and formatted. The final version may differ from this version.



Running title: MicroRNA regulates human CYP24

To whom all correspondence should be sent:

Tsuyoshi Yokoi, Ph.D.,

Drug Metabolism and Toxicology

Faculty of Pharmaceutical Sciences

Kanazawa University

Kakuma-machi, Kanazawa 920-1192, Japan

Tel / Fax +81-76-234-4407

E-mail: tyokoi@kenroku.kanazawa-u.ac.jp

Number of text pages: 18

Number of tables: 0

Number of figures: 5

Number of references: 36

Abstract: 247 words

Introduction: 386 words

Discussion: 899 words

Abbreviations: CYP, cytochrome P450; $1,25(OH)_2D_3$, 1α,25-dihydroxyvitamin $D_3$; miRNA, microRNA; MRE125b, miR-125b recognition element; AsO, antisense oligonucleotide; UTR, untranslated region.

Molecular Pharmacology Fast Forward. Published on July 1, 2009 as DOI: 10.1124/mol.109.056986
This article has not been copyedited and formatted. The final version may differ from this version.



## Abstract

Human vitamin $D_3$ hydroxylase (CYP24) catalyzes the inactivation of 1α,25-dihydroxyvitamin $D_3$ (calcitriol), which exerts antiproliferative effects. CYP24 has been reported to be overexpressed in various cancers, in which microRNAs (miRNAs) levels are dysregulated. In silico analysis identified a potential miR-125b recognition element (MRE125b) in the 3'-untranslated region of human CYP24 mRNA. We investigated whether CYP24 is regulated by miR-125b. In luciferase assays using a reporter plasmid containing MRE125b, transfection of the antisense oligonucleotide (AsO) for miR-125b increased the reporter activity in KGN cells and transfection of precursor miR-125b decreased the reporter activity in MCF-7 cells. The endogenous CYP24 protein level was also increased by AsO for miR-125b in KGN cells and was decreased by precursor miR-125b in MCF-7 cells. These results suggested that human CYP24 is regulated by miR-125b. Immunohistochemical analysis revealed that the CYP24 protein levels in human breast cancer were higher than in adjacent normal tissues, without an accompanying CYP24 mRNA increase. On the other hand, the expression levels of miR-125b in cancer tissues were significantly ($P < 0.0005$) lower than those in normal tissues. Interestingly, the CYP24 protein levels in cancer tissues were inversely associated with the cancer/normal ratios of the miR-125b levels, indicating that the decreased miR-125b levels in breast cancer tissues would be one of the causes of the high CYP24 protein expression. In conclusion, this study clearly demonstrated that miR-125b post-transcriptionally regulates the CYP24, which serve as a possible mechanism for the high CYP24 expression in cancer tissues.

Molecular Pharmacology Fast Forward. Published on July 1, 2009 as DOI: 10.1124/mol.109.056986
This article has not been copyedited and formatted. The final version may differ from this version.



## Introduction

Human CYP24 is a key enzyme involved in the inactivation of 1α,25-dihydroxyvitamin $D_3$ ($1,25(OH)_2D_3$, calcitriol). $1,25(OH)_2D_3$ is classically considered as a regulator of calcium homeostasis, but it has now received much interest for its antitumor activity (Deeb et al., 2007). For ensuring appropriate biological effects of $1,25(OH)_2D_3$, the balance between bioactivation and inactivation is critical. CYP24 has been reported to be overexpressed in various tumor cells (Deeb et al., 2007). Since CYP24 limits the biological activity of the vitamin D signaling system, the overexpression may abrogate the vitamin D-mediated growth control. In fact, it has been reported that the overexpression of CYP24 is associated with poor prognosis and overall reduced survival in patients with esophageal cancer (Mimori et al., 2004). As for the cause of the CYP24 overexpression, an amplification of the chromosomal region 20q13.2, where the *CYP24* gene is located, in human breast cancer was reported (Albertson et al., 2000; Kallioniemi et al., 1994). Albertson et al (2000) found that the relative levels of CYP24 mRNA were higher in breast cancers with the amplification, although the number of samples was only 3. Townsend et al (2005) also reported increased CYP24 mRNA levels in breast cancers. On the other hand, de Lyra et al (2006) reported that there was no difference in the CYP24 mRNA levels between breast cancer and normal tissues. In contrast, Anderson et al (2006) reported that CYP24 mRNA was down-regulated in breast cancer relative to normal tissues. Although we cannot compare these expression profiles since the genetic background is heterogeneous in different breast cancer cells (Hicks et al., 2006), the overexpression of CYP24 protein is not necessarily associated with the increased CYP24 mRNA level. This background allowed us to postulate the involvement of a post-transcriptional mechanism in CYP24 regulation.

MicroRNAs (miRNAs) are endogenous ~22-nucleotide non-coding RNAs that regulate gene expression through the translational repression or degradation of target mRNAs (Bartel, 2004). The human genome may contain up to 1000 miRNAs and 30% of

Molecular Pharmacology Fast Forward. Published on July 1, 2009 as DOI: 10.1124/mol.109.056986
This article has not been copyedited and formatted. The final version may differ from this version.



human mRNAs are predicted to be targets of miRNAs (Lewis et al., 2005). Accumulating evidence has revealed an important role of miRNAs in cancer (Medina and Slack, 2008). In various cancers, the miRNA levels are dysregulated (Lu et al., 2005). In the present study, we investigated whether miRNAs may be involved in the regulation of the human CYP24 expression.

Molecular Pharmacology Fast Forward. Published on July 1, 2009 as DOI: 10.1124/mol.109.056986
This article has not been copyedited and formatted. The final version may differ from this version.



## Materials and Methods

**Chemicals and reagents.** $1,25(OH)_2D_3$ and corticosterone were purchased from Wako Pure Chemical Industries (Osaka, Japan). $25(OH)D_3$ and $24,25(OH)_2D_3$ were from Funakoshi (Tokyo, Japan). The pGL3-promoter vector, phRL-TK plasmid, Tfx-20 reagent, and a dual-luciferase reporter assay system were purchased from Promega (Madison, WI). LipofectAMINE2000 and LipofectAMINE RNAiMAX were from Invitrogen (Carlsbad, CA). Pre-miR miRNA precursors for miR-125b-1 and negative control #2 were from Ambion (Austin, TX). Antisense LNA/DNA mixed oligonucleotides (AsO) for miR-125b (5'-TCACAAGTTAGGGTCTCAGGGA-3', underlined letters show LNA) and for negative control (5'-AGACTAGCGGTATCTTAAACC-3') were from Greiner Japan (Tokyo, Japan). All primers and oligonucleotides were commercially synthesized at Hokkaido System Sciences (Sapporo, Japan). Goat anti-human CYP24 polyclonal antibodies and Alexa Fluor 680 donkey anti-goat IgG were from Santa Cruz Biotechnology (Santa Cruz, CA) and Invitrogen, respectively. All other chemicals and solvents were of the highest grade commercially available.

**Cells and culture conditions.** The human breast adenocarcinoma cell lines MCF-7 and MDA-MB-435, and the human embryonic kidney cell line HEK293 were obtained from the American Type Culture Collection (Rockville, MD). The human ovarian granulosa-like tumor cell line KGN (Nishi et al., 2001) and the human hepatoma cell line HepG2 were obtained from Riken Gene Bank (Tsukuba, Japan). MCF-7 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Nissui Pharmaceutical, Tokyo, Japan) supplemented with 0.1 mM nonessential amino acid (Invitrogen) and 10% fetal bovine serum (FBS) (Invitrogen). MDA-MB-435 cells and HepG2 cells were cultured in DMEM supplemented with 10% FBS. HEK293 cells were cultured in DMEM supplemented with 4.5 g/L glucose, 10 mM HEPES, and 10% FBS. KGN cells were cultured in a 1:1 mixture of DMEM and Ham's F-12 medium (Nissui Pharmaceutical) supplemented with 10% FBS.

Molecular Pharmacology Fast Forward. Published on July 1, 2009 as DOI: 10.1124/mol.109.056986
This article has not been copyedited and formatted. The final version may differ from this version.



These cells were maintained at 37°C under an atmosphere of 5% $CO_2$-95% air.

**Northern blot analysis and real-time RT-PCR for mature miR-125b.** Total RNA (20 μg) isolated from the cells using ISOGEN (Nippon Gene, Tokyo, Japan) was separated on 15% denaturing polyacrylamide gels containing 8 M urea. The RNA was then electrophoretically transferred to Zeta-Probe GT Genomic Tested Blotting Membranes (Bio-Rad, Hercules, CA). The membranes were probed with $^{32}$P-labelled DNA probe for miR-125b (5'-TCA CAA GTT AGG GTC TCA GGG A-3'), and then the miRNAs were detected and quantified with a Fuji Bio-Imaging Analyzer BAS 1000 (Fuji Film, Tokyo, Japan).

For quantification of mature miR-125b, polyadenylation and reverse transcription were performed using an NCode miRNA First-Strand cDNA Synthesis Kit (Invitrogen) according to the manufacturer's protocol. The forward primer for miR-125b was 5'-TCC CTG AGA CCC TAA CTT GTG A-3', and the reverse primer was the supplemented universal qPCR primer. The real-time PCR was performed using the Smart Cycler (Cepheid, Sunnyvale, CA) with Smart Cycler software (version 1.2b) as follows: after an initial denaturation at 95°C for 30 s, the amplification was performed by denaturation at 95°C for 10 s, annealing and extension at 60°C for 10 s for 45 cycles.

**SDS-PAGE and Western blot analyses for CYP24 protein and real-time RT-PCR for CYP24 mRNA.** Whole cell lysates were prepared by homogenization with lysis buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, 1% NP-40) containing protease inhibitors [0.5 mM APMSF, 2 μg/mL aprotinin, 2 μg/mL leupeptin]. The protein concentrations were determined using Bradford protein assay reagent (Bio-Rad). The whole cell lysates (20 μg) were separated by 10% SDS-polyacrylamide gel electrophoresis and transferred to Immobilon-P transfer membrane (Millipore, Bedford, MA). The membrane was probed with goat anti-human CYP24 antibodies and Alexa Fluor 680 donkey anti-goat IgG antibodies. The band densities were quantified using the Odyssey Infrared Imaging System (LI-COR Biosciences, Cambridge, UK).

Molecular Pharmacology Fast Forward. Published on July 1, 2009 as DOI: 10.1124/mol.109.056986
This article has not been copyedited and formatted. The final version may differ from this version.



The cDNAs were synthesized from total RNAs using ReverTra Ace (Toyobo, Osaka, Japan). The forward and reverse primers for CYP24 mRNA were 5'-CAG CAA ACA GTC TAA TGT GG-3' and 5'-AGC ATA TTC ACC CAG AAC TG-3', respectively. The real-time RT-PCR analysis was performed as follows: after an initial denaturation at 95°C for 30 sec, the amplification was performed by denaturation at 94°C for 4 sec, annealing and extension at 62°C for 20 sec for 45 cycles. The CYP24 mRNA levels were normalized with GAPDH mRNA determined by real-time RT-PCR as described previously (Tsuchiya et al., 2004).

**Construction of reporter plasmids.** To construct luciferase reporter plasmids, various target fragments were inserted into the *Xba*I site, downstream of the luciferase gene in the pGL3-promoter vector. The sequence from +1575 to +1592 in the human *CYP24* gene (5'-TCA TAT CCA ACT CAG GGA-3') was termed miR-125b recognition element (MRE125b). The fragment containing three copies of the MRE125b, 5'-CTA GAT TTG CTA ACA *TCA TAT CCA ACT CAG GGA* AGC GGA TTT GCT AAC A*TC ATA TCC AAC TCA GGG A*AG CGG ATT TGC TAA CA*T CAT ATC CAA CTC AGG GA*A GCG GAT-3' (MRE125b is italicized), was cloned into the pGL3-promoter vector (pGL3/MRE3). The complementary sequence was also cloned into the pGL3-promoter vector (pGL3/MRE3rev). A fragment containing the perfect matching sequence with the mature miR-125b, 5'-CTA GA*T CAC AAG TTA GGG TCT CAG GGA* T -3' (the matching sequence is italicized), was cloned (pGL3/c-miR-125b). A fragment containing the sequence from +1529 to +1609 was cloned, resulting in single (pGL3/UTR1) and double (pGL3/UTR2) forward insertions as well as a single reverse insertion (pGL3/UTR1rev). The nucleotide sequences of the constructed plasmids were confirmed by DNA sequencing analyses.

**Luciferase assay.** Various pGL3 plasmids were transiently transfected with phRL-TK plasmid into KGN and MCF-7 cells. Briefly, the day before transfection, the KGN cells (8 x $10^4$ cells/well) and MCF-7 cells (4 x $10^4$ cells/well) were seeded into 24-well plates. After

Molecular Pharmacology Fast Forward. Published on July 1, 2009 as DOI: 10.1124/mol.109.056986
This article has not been copyedited and formatted. The final version may differ from this version.



24 hr, 450 ng of pGL3 plasmid and 50 ng of phRL-TK plasmid were transfected using Tfx-20 reagent. To KGN cells, 3.5 pmol of AsOs for miR-125b or control were co-transfected using LipofectAMINE 2000, and to MCF-7 cells, 0.25 pmol of precursors for miR-125b-1 or control were co-transfected using Tfx-20 reagent. After incubation for 48 hr, the cells were resuspended in passive lysis buffer and then the luciferase activity was measured with a luminometer (Wallac, Turku, Finland) using the dual-luciferase reporter assay system.

**Assessment of the endogenous CYP24 expression level in KGN and MCF-7 cells.** To investigate the effects of miR-125b on the expression of endogenous CYP24 protein, 50 nM precursors or 50 nM AsOs for miR-125b or control were transfected into KGN ($4 \times 10^5$ cells/well) and MCF-7 cells ($2.5 \times 10^5$ cells/well), respectively, on 6-well plates using LipofectAMINE RNAiMAX. After 72 h, total RNA was isolated using ISOGEN and the mature miR-125b levels were determined by Northern blot analysis. Whole cell lysate was prepared and the CYP24 protein level was determined by Western blot analysis. The CYP24 protein levels were normalized with the β-actin protein levels determined with rabbit anti-human β-actin antibodies (BioVision, Mountain View, CA) and IRDye 680 goat anti-rabbit IgG antibodies (LI-COR Biosciences). To determine the CYP24 enzymatic activity, $24,25(OH)_2D_3$ formation from $25(OH)D_3$ was measured. The KGN and MCF-7 cells seeded on 6-well plates were transfected with AsO and precursor as described above. After 24 hr, the cells were treated with 50 nM $1,25(OH)_2D_3$ for 24 hours to induce CYP24 expression. The cells were then incubated with $25(OH)D_3$ in the medium supplemented with 3% FBS for 18 hours. To the collected medium, corticosterone was added as an internal standard. The medium was extracted with 4 volumes of chloroform/methanol (3:1). The organic phase was recovered and dried. The resulting residue was dissolved with 50% acetonitrile and was subjected to HPLC. Used column was an YMC-Pack ODS-A (6.0 x 300 mm, 5 μm) column (YMC, Tokyo, Japan) and column temperature was 35°C. The mobile phase was 55% acetonitrile containing 0.2% acetic acid (A) and 90% acetonitrile (B).

Molecular Pharmacology Fast Forward. Published on July 1, 2009 as DOI: 10.1124/mol.109.056986
This article has not been copyedited and formatted. The final version may differ from this version.



The condition for elution was as follows: 0%B (0 – 40 min); 0 – 100%B (40 – 50 min); 100%B (50 – 60 min); 100 – 0%B (60 – 65 min). Linear gradients were used for all solvent changes. The flow rate was 1.0 ml/min. The eluent was monitored at 265 nm. The retention times of corticosterone, 24,25$(OH)_2D_3$, and 25$(OH)D_3$ were 9 min, 41 min, and 61 min, respectively. The quantification of the metabolite was performed by comparing the HPLC peak height to that of an authentic standard with reference to the internal standard.

**Human breast cancer and adjacent normal tissues.** This study was approved by the Ethics Committee of Kanazawa University (Kanazawa, Japan). Written informed consent was obtained prior to their participation in this study. Breast cancer and adjacent normal tissues were obtained as surgical samples from 14 Japanese patients with primary breast carcinoma. The patients (42 to 77 years old) had not undergone chemotherapy. Thirteen patients were invasive ductal carcinoma and one patient was invasive lobular carcinoma. The histological grade was determined by standard criteria as grade 1-2 (n = 9), grade 2 (n = 4), and grade 2-3 (n = 1). The samples were obtained immediately after resection, divided into breast cancer and adjacent normal tissues, and immediately frozen with liquid nitrogen. The samples were stored at -80°C until use. The expression levels of mature miR-125b were determined by real-time RT-PCR and were normalized with the 18S rRNA levels determined by real-time RT-PCR as follows: the forward and reverse primers were 5'-GGC CCT GTA ATT GGA ATG AGT C-3' and 5'-GAC ACT CAG CTA AGA GCA TCG-3', respectively. After an initial denaturation at 95°C for 30 sec, the amplification was performed by denaturation at 94°C for 10 sec, annealing and extension at 68°C for 20 sec for 30 cycles.

**Immunohistochemistry.** Immunohistochemical analyses of CYP24 were performed using formalin-fixed, paraffin-embedded specimens of breast cancer tissues from 14 patients. The sections were soaked in Liberate Antibody Binding Solution (Polysciences, Warrington, PA) at room temperature for 10 min, and then incubated with anti-human CYP24 antibodies at

Molecular Pharmacology Fast Forward. Published on July 1, 2009 as DOI: 10.1124/mol.109.056986
This article has not been copyedited and formatted. The final version may differ from this version.



4°C for 16 h. Staining was performed using a VECTASTAIN ABC kit. The extent of immunostaining in cancer cells was evaluated by the intensity of staining, dividing the samples into three groups (low, medium, and high levels).

**Statistical analyses.** Data are expressed as mean ± SD of triplicate determinations or three independent experiments. Statistical significance was determined by analysis of variance and Dunnett multiple comparisons test. Comparison of two groups was made with an unpaired, two-tailed student's *t* test. Correlation analysis was performed by Spearman's rank method. The statistical significance of difference between the expression level of miR-125b in breast cancer and normal tissues was determined by paired, two-tailed student's *t* test. The relationship between the CYP24 protein level and the cancer/normal ratio in miR-125b level was investigated by analysis of variance and Tukey method test. A value of $P < 0.05$ was considered statistically significant.

Molecular Pharmacology Fast Forward. Published on July 1, 2009 as DOI: 10.1124/mol.109.056986
This article has not been copyedited and formatted. The final version may differ from this version.



## Results

**miR-125b interacts with the 3'-UTR of human CYP24 mRNA.** Computational predictions using the microRNA targets web site (http://www.targetscan.org/) indicate that miR-125b shares complementarity with a sequence in the 3'-UTR of the CYP24 mRNA at +1575 to +1592 (energy -21.6 kcal/mol) (Fig. 1). This region was termed the miR-125b recognition element (MRE125b). The seed sequence (nucleotides 2 to 7) of miR-125b was perfectly matched with the predicted binding site of the CYP24 mRNA. In this study, we investigated whether miR-125b might be involved in the regulation of human CYP24 expression through the MRE125b.

**miR-125b and CYP24 are differentially expressed in human cell lines.** The expression levels of mature miR-125b in MCF-7, MDA-MB-435, KGN, HepG2, and HEK293 cells were determined by Northern blot analysis. KGN and MDA-MB-435 cells showed a clear band of mature miR-125b, but the other cell lines did not (Fig. 2A). We also performed real-time RT-PCR analysis using NCode miRNA First-Strand cDNA Synthesis Kit (Fig. 2B) to detect the mature miR-125b, because this method is more sensitive than Northern blot analysis. Extremely low levels of the mature miR-125b were detected in MCF-7, HepG2, and HEK293 cells. The CYP24 protein levels were determined by Western blot analyses (Fig. 2C) and the CYP24 mRNA levels were determinxed by real-time RT-PCR (Fig. 2D). The CYP24 protein levels were not positively correlated ($Rs$ = -0.100, $P$ = 0.950) with the CYP24 mRNA levels, indicating the post-transcriptional regulation of CYP24. Interestingly, a trend of inverse association between the CYP24 protein levels and the mature miR-125b levels was found ($Rs$ = -0.900, $P$ = 0.083).

**MRE125b in CYP24 is a target of posttranscriptional repression by miR-125b.** To investigate whether MRE125b is functional in the regulation by miR-125b, luciferase assays were performed. The pGL3/MRE3 plasmid containing three copies of the MRE125b was

Molecular Pharmacology Fast Forward. Published on July 1, 2009 as DOI: 10.1124/mol.109.056986
This article has not been copyedited and formatted. The final version may differ from this version.



used since it is known that the multiplicity of the binding site allows efficaciously detecting the effects of miRNA. The pGL3/UTR1 plasmid was used to investigate whether the intact 3'-UTR sequence of CYP24 including MRE125b can be recognized by miRNA. The pGL3/UTR2 plasmid was used to confirm whether the multiplicity could intensify the effects of miRNA. The pGL3/c-miR-125b plasmid containing the perfect matching sequence with the mature miR-125b was used as a positive control. These plasmids were transfected into the KGN cells showing the highest expression of miR-125b (Fig. 2A). We first confirmed that the luciferase activity of the pGL3/c-miR-125b plasmid was significantly ($P < 0.01$) lower than that of the control pGL3-promoter and was significantly ($P < 0.005$) restored by the transfection of AsO for miR-125b (Fig. 3). The reporter activity of the pGL3/MRE3 plasmid was also significantly lower than that of the control plasmid, and it was significantly ($P < 0.01$) restored by the transfection of AsO for miR-125b. The reporter activities of the pGL3/UTR1 and pGL3/UTR2 were also significantly lower than that of the control plasmid, and the activity of pGL3/UTR2 was significantly ($P < 0.05$) restored by the transfection of AsO for miR-125b. Next, to investigate the effect of the overexpression of miR-125b on the luciferase activity, the precursor for miR-125b was transfected in MCF-7 cells, in which the endogenous miR-125b level was low. The overexpression of miR-125b significantly decreased the luciferase activities of the pGL3/c-miR-125b, pGL3/MRE3, pGL3/UTR1, and pGL3/UTR2 plasmids. These results suggest that miR-125b recognized the MRE125b on the human CYP24 mRNA and regulated the expression.

**Endogenous CYP24 levels are regulated by miR-125b.** We investigated the effects of inhibition of miR-125b on the CYP24 protein level and enzymatic activity in KGN cells. Northern blot analysis confirmed that the endogenous miR-125b level was prominently decreased by the transfection of the AsO for miR-125b (Fig. 4A). As shown in Fig. 4B, the CYP24 protein level was significantly ($P < 0.005$) increased (1.4 fold) by the transfection of the AsO for miR-125b. The 25(OH)$D_3$ 24-hydroxylase activity was also increased by the

Molecular Pharmacology Fast Forward. Published on July 1, 2009 as DOI: 10.1124/mol.109.056986
This article has not been copyedited and formatted. The final version may differ from this version.



transfection of the AsO, although the difference was statistically insignificant (Fig. 4C). We next investigated the effects of overexpression of miR-125b on the CYP24 protein level and enzymatic activity in MCF-7 cells. Northern blot analysis confirmed that the mature miR-125b level was prominently increased by the transfection of the precursor for miR-125b (Fig. 4A). As shown in Fig. 4B, the CYP24 protein level was significantly ($P < 0.05$) decreased (70% of control) by the transfection of the precursor for miR-125b. The 25(OH)$D_3$ 24-hydroxylase activity was also significantly ($P < 0.05$) decreased by the transfection of the precursor (Fig. 4C). These results suggest that miR-125b regulates the endogenous CYP24 level.

**CYP24 protein levels are inversely associated with miR-125b levels in human breast cancer.** To investigate whether miR-125b affects the CYP24 expression *in vivo*, we used breast cancer tissues from 14 patients. The expression levels of CYP24 protein in breast cancer were determined by immunohistochemistry (Fig. 5A). All of the breast tissues showed cytoplasmic immunoreactivity for CYP24. The CYP24 protein levels were higher in cancer tissues than in adjacent normal tissues. The extent of CYP24 staining in cancer tissues varied among individuals. No staining was observed in normal goat IgG. As regards the CYP24 mRNA, the levels normalized with GAPDH mRNA were lower in cancer tissues than in normal tissues (data not shown). This was due to the increased levels of GAPDH mRNA in the cancer tissues. When the non-normalized CYP24 mRNA levels in the cancer and normal tissues were compared, there was no difference. In addition, no difference was observed in the CYP24 mRNA levels normalized with the 18S rRNA levels in the cancer and normal tissues (data not shown). Thus, the higher levels of CYP24 protein in cancer tissues would not be due to the increased CYP24 mRNA levels. As shown in Fig. 5B, the mature miR-125b levels normalized with the 18S rRNA levels in the cancer tissues were significantly ($P < 0.0005$) lower than those in normal tissues, in agreement with previous studies (Calin et al., 2004; Iorio et al., 2005). Interestingly, an inverse association was observed between the CYP24 protein levels in breast cancer tissue and the cancer/normal

Molecular Pharmacology Fast Forward. Published on July 1, 2009 as DOI: 10.1124/mol.109.056986
This article has not been copyedited and formatted. The final version may differ from this version.



ratio of mature miR-125b levels (Fig. 5C). These results suggested that the decrease of miR-125b would be one of the causes of the high expression of CYP24 protein in breast cancer tissues. No association was observed between the levels of CYP24 or miR-125b and the biopathologic features (estrogen receptor and progesterone receptor levels and the presence or absence of lymph node metastasis) and the tumor stage of breast cancer (data not shown). Thus, the pathological characteristics would not affect the inverse association between the CYP24 and miR-125b levels.

Molecular Pharmacology Fast Forward. Published on July 1, 2009 as DOI: 10.1124/mol.109.056986
This article has not been copyedited and formatted. The final version may differ from this version.



**Discussion**

In the present study, we investigated whether human CYP24, which catalyzes the inactivation of $1,25(OH)_2D_3$, might be a target of miRNA. In silico analysis identified MRE125b in the 3'-UTR in CYP24 mRNA. The luciferase assay revealed that the endogenous and exogenous miR-125b negatively regulated the activity through MRE125b. Consistent with previous reports (Wang et al., 2006; Tsuchiya et al., 2006), the repression was increased by multiplicity of the binding site. The AsO for miR-125b restored the luciferase activity. These results suggest that the MRE125b is functionally recognized by miR-125b. The overall complementarity of MRE125b for miR-125b is low, but the seed sequence of miR-125b was perfectly matching. Therefore, the seed sequence matching and accessibility of CYP24 would allow access to miR-125b. Furthermore, the endogenous CYP24 protein level was increased by the inhibition of miR-125b and was decreased by the overexpression of miR-125b. These results clearly indicated that human CYP24 is post-transcriptionally regulated by miR-125b.

Previously, it was reported that human CYP24 is regulated by transcription factors such as vitamin D receptor (VDR) (Chen and DeLuca, 1995), pregnane X receptor (Pascussi et al., 2005), constitutive androstane receptor (Moreau et al., 2007), and silencing mediator for retinoid and thyroid hormone receptors (Konno et al., 2009). A recent study also reported that the DNA methylation status affects the basal and VDR-dependent promoter activity of CYP24 (Chung et al., 2007; Novakovic et al., 2009). Cui et al (2009) recently reported that the ERK signaling pathway is involved in the$1,25(OH)_2D_3$-mediated CYP24 induction. In addition to these transcriptional regulation mechanisms, we found that the CYP24 expression is post-transcriptionally regulated by miRNA. Thus, this study provides new insight into the regulation mechanisms of human CYP24.

This is the first report, to our knowledge, demonstrating by immunohistochemistry that CYP24 protein is elevated in human breast cancer tissues. The increased expression of CYP24 would be due to the decreased expression of miR-125b in human breast cancer

Molecular Pharmacology Fast Forward. Published on July 1, 2009 as DOI: 10.1124/mol.109.056986
This article has not been copyedited and formatted. The final version may differ from this version.



tissues. Mature miR-125b is formed by two precursors, miR-125b-1 and miR-125b-2, which are located in chromosomes 11q24.1 and 21q11.2, respectively (http://microrna.sanger.ac.uk/sequences/). It has been reported that the chromosome regions 11q23-24 (Negrini et al., 1995) and 21q11-21 (Yamada et al., 2008) are frequently deleted in breast cancers. This could be one of the mechanisms of the down-regulation of miR-125b in breast cancer.

Interestingly, we recently found that human VDR is also regulated by miR-125b (Mohri et al., 2009). Therefore, the up-regulation of VDR in breast cancer by the down-regulation of miR-125b may partly contribute to the up-regulation of CYP24. The increase of CYP24 level would attenuate antitumor activity of $1,25(OH)_2D_3$. In contrast, the increase of VDR level would augment the antitumor activity of $1,25(OH)_2D_3$. In our recent study (Mohri et al., 2009), we investigated the effects of miR-125b on the antiproliferative effects of $1,25(OH)_2D_3$ by evaluating the growth of MCF-7 cells. We found that the cell growth was significantly inhibited by $1,25(OH)_2D_3$, however, the inhibited cell growth was prominently diminished by the overexpression of miR-125b (Mohri et al., 2009). Accordingly, it is considered that the effects of miR-125b could be stronger for VDR rather than for CYP24 in this breast cancer cell line. A possible explanation for this observation is that the CYP24 protein level in the MCF-7 cells might be too low to inactivate the exogenously added $1,25(OH)_2D_3$.

The miR-125b has been considered as a tumor suppressor gene, since it can suppress the expression of *ERBB2* and *ERBB3* oncogenes (Scott et al., 2007). In addition, it has been reported that miR-125b inhibited the cell proliferation of human breast cancer cells (Scott et al., 2007), hepatocellular carcinoma cells (Li et al., 2008), and thyroind carcinoma cells (Visone et al., 2007). In contrast, Lee et al (2005) have reported that inhibition of miR-125b resulted in the decrease of growth of human prostate cancer cells. Since the miR-125b expression differently changes in human tumors; that the miR-125b is down-regulated in breast, ovarian, and bladder cancers but is up-regulated in pancreas and stomach cancers (Volinia et al., 2006), it can be hypothesized that the miR-125b acts in different way

Molecular Pharmacology Fast Forward. Published on July 1, 2009 as DOI: 10.1124/mol.109.056986
This article has not been copyedited and formatted. The final version may differ from this version.



depending on the cellular context. Mizuno et al (2008) have recently reported that miR-125b is involved in osteoblastic differentiation through the regulation of cell proliferation. Since we found the role of miR-125b in controlling the level and action of $1,25(OH)_2D_3$, it is also interesting to know the function of miR-125b for normal calcium and bone homeostasis in the future.

In the miRNA field, rapid progress has been made in the previous half decade. The roles of miRNA in biological processes such as cell proliferation, development, and apoptosis as well as various diseases such as cancer, cardiovascular diseases, Alzheimer's disease have become recognized (Erson and Petty, 2008; Garofalo et al., 2008). Information concerning the targets of miRNA is increasing. However, among a large number of cytochrome P450 isoforms, the currently known isoforms that were identified as targets of miRNA are only human CYP1B1 (Tsuchiya et al., 2006), rat CYP2A3 (Kalscheuer et al., 2008), and human CYP24 in this study. Further studies are required to understand the contribution of miRNAs to the regulation of drug-metabolizing enzymes in relation to their physiological roles.

In conclusion, we found that human CYP24 is post-transcriptionally regulated by miR-125b, which would serve as a possible mechanism for the high CYP24 expression in cancer tissues. This study could provide new insight into the regulatory mechanism of human CYP24.

Molecular Pharmacology Fast Forward. Published on July 1, 2009 as DOI: 10.1124/mol.109.056986
This article has not been copyedited and formatted. The final version may differ from this version.



**Acknowledgements**

The enthusiasm and research support of Noriko Kawagishi, Futaba Breast Clinic, is greatly appreciated. We are grateful to Dr. Toshiyuki Sakaki, Toyama Prefectural University for providing recombinant human CYP24 as a positive control. We acknowledge Mr. Brent Bell for reviewing the manuscript.

Molecular Pharmacology Fast Forward. Published on July 1, 2009 as DOI: 10.1124/mol.109.056986
This article has not been copyedited and formatted. The final version may differ from this version.



**References**

Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, Kuo WL, Gray JW, and Pinkel D (2000) Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. *Nat Genet* **25:**144-146.

Anderson MG, Nakane M, Ruan X, Kroeger PE, and Wu-Wong JR (2006) Expression of VDR and CYP24A1 mRNA in human tumors. *Cancer Chemother Pharmacol* **57:**234-240.

Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* **116:**281-297.

Chen KS and DeLuca HF (1995) Cloning of the human 1α,25-dihydroxyvitamin D-3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements. *Biochim Biophys Acta* **1263:**1-9.

Chung I, Karpf AR, Muindi JR, Conroy JM, Nowak NJ, Johnson CS, and Trump DL (2007) Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriol. *J Biol Chem* **282:**8704-8714.

Cui M, Zhao Y, Hance KW, Shao A, Wood RJ, and Fleet JC (2009) Effects of MAPK signaling on 1,25-dihydroxyvitamin D-mediated CYP24 gene expression in the enterocyte-like cell line, Caco-2. *J Cell Physiol* **219:**132-142.

Deeb KK, Trump DL, and Johnson CS (2007) Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. *Nat Rev Cancer* **7:**684-700.

de Lyra EC, da Silva IA, Katayama ML, Brentani MM, Nonogaki S, Góes JC, and Folgueira MA (2006) 25(OH)$D_3$ and 1,25$(OH)_2D_3$ serum concentration and breast tissue expression of 1α-hydroxylase, 24-hydroxylase and Vitamin D receptor in women with and without breast cancer. *J Steroid Biochem Mol Biol* **100:**184-192.

Erson AE and Petty EM (2008) MicroRNAs in development and disease. *Clin Genet* **74:**296-306.

Garofalo M, Condorelli G, and Croce CM (2008) MicroRNAs in diseases and drug response.

*Curr Opin Pharmacol* **8:**661-667.

Hicks J, Krasnitz A, Lakshmi B, Navin NE, Riggs M, Leibu E, Esposito D, Alexander J, Troge J, Grubor V, Yoon S, Wigler M, Ye K, Børresen-Dale AL, Naume B, Schlicting E, Norton L, Hägerström T, Skoog L, Auer G, Månér S, Lundin P, and Zetterberg A (2006) Novel patterns of genome rearrangement and their association with survival in breast cancer. *Genome Res* **16:**1465-1479.

Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, and Croce CM (2005) MicroRNA gene expression deregulation in human breast cancer. *Cancer Res* **65:**7065-7070.

Kallioniemi A, Kallioniemi OP, Piper J, Tanner M, Stokke T, Chen L, Smith HS, Pinkel D, Gray JW, and Waldman FM (1994) Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. *Proc Natl Acad Sci USA* **91:**2156-2160.

Kalscheuer S, Zhang X, Zeng Y, and Upadhyaya P (2008) Differential expression of microRNAs in early-stage neoplastic transformation in the lungs of F344 rats chronically treated with the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. *Carcinogenesis* **29:**2394-2399.

Konno Y, Kodama S, Moore R, Kamiya N, and Negishi M (2009) Nuclear xenobiotic receptor pregnane X receptor locks corepressor silencing mediator for retinoid and thyroid hormone receptors (SMRT) onto the *CYP24A1* promoter to attenuate vitamin $D_3$ activation. *Mol Pharmacol* **75:**265-271.

Lee YS, Kim HK, Chung S, Kim KS, and Dutta A (2005) Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the down-regulation of putative targets during differentiation. *J Biol Chem* **280:**16635-16641.

Lewis BP, Burge CB, and Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* **120:**15-20.

Li W, Xie L, He X, Li J, Tu K, Wei L, Wu J, Guo Y, Ma X, Zhang P, Pan Z, Hu X, Zhao Y, Xie H, Jiang G, Chen T, Wang J, Zheng S, Cheng J, Wan D, Yang S, Li Y, and Gu J (2008) Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. *Int J Cancer* **123:**1616-1622.

Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mark RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, and Golub TR (2005) MicroRNA expression profiles classify human cancers. *Nature* **435:**834-838.

Medina PP and Slack FJ (2008) microRNAs and cancer: an overview. *Cell Cycle* **7:**2485-2492.

Mimori K, Tanaka Y, Yoshinaga K, Masuda T, Yamashita K, Okamoto M, Inoue H, and Mori M (2004) Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer. *Ann Oncol* **15:**236-241.

Mizuno Y, Yagi K, Tokuzawa Y, Kanesaki-Yatsuka Y, Suda T, Katagiri T, Fukuda T, Maruyama M, Okuda A, Amemiya T, Kondoh Y, Tashiro H, and Okazaki Y (2008) MiR-125b inhibits osteoblastic differentiation by down-regulation of cell proliferation. *Biochem Biophys Res Commun* **368:**267-272.

Mohri T, Nakajima M, Takagi S, Komagata S, and Yokoi T (2009) MicroRNA regulates human vitamin D receptor. *Int J Cancer*, in press.

Moreau A, Maurel P, Vilarem MJ, and Pascussi JM (2007) Constitutive androstane receptor-vitamin D receptor crosstalk: consequence on *CYP24* gene expression. *Biochem Biophys Res Commun* **360:**76-82.

Negrini M, Rasio D, Hampton GM, Sabbioni S, Rattan S, Carter SL, Rosenberg AL, Schwartz GF, Shiloh Y, Cavenee WK, and Croce CM (1995) Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: identification of a new region at 11q23.3. *Cancer Res* **55:**3003-3007.

Nishi Y, Yanase T, Mu YM, Oba K, Ichino I, Saito M, Nomura M, Mukasa C, Okabe T, Goto K, Takayanagi R, Kashimura Y, Haji M, and Nawata H (2001) Establishment and characterization of a steroidogenic human granulose-like tumor cell line, KGN, that expresses functional follicle-stimulating hormone receptor. *Endocrinology* **142:**437-445.

Novakovic B, Sibson M, Ng HK, Manuelpillai U, Rakyan VK, Down TA, Beck S, Fournier T, Evain-Brion D, Dimitriadis E, Craig JM, Morley R, and Saffery R (2009) Placenta specific methylation of the vitamin D 24-hydroxylase gene: Implications for feedback autoregulation of active vitamin D levels at the fetomaternal interface. *J Biol Chem* in press.

Pascussi JM, Robert A, Nguyen M, Walrant-Debray O, Garabedian M, Martin P, Pineau T, Saric J, Navarro F, Maurel P, and Vilarem MJ (2005) Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. *J Clin Invest* **115:**177-186.

Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, and Benz CC (2007) Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. *J Biol Chem* **282:**1479-1486.

Townsend K, Banwell CM, Guy M, Colston KW, Mansi JL, Stewart PM, Campbell MJ, and Hewison M (2005) Autocrine metabolism of vitamin D in normal and malignant breast tissue. *Clin Cancer Res* **11:**3579-3586.

Tsuchiya Y, Nakajima M, Kyo S, Kanaya T, Inoue M, and Yokoi T (2004) Human CYP1B1 is regulated by estradiol via estrogen receptor. *Cancer Res* **64:**3119-3125.

Tsuchiya Y, Nakajima M, Takagi S, Taniya T, and Yokoi T (2006) MicroRNA regulates the expression of human cytochrome P450 1B1. *Cancer Res* **66:**9090-9098.

Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, Volinica S, Coluzzi S, Leone V, Borbone E, Liu C-G, Petrocca F, Troncone G, Caalin GA, Scarpa A, Colato C, Tallini G, Santoro M, Croce CM, and Fusco A (2007) Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. *Oncogene*

**26:**7590-7595.

Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, and Croce CM (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc Natl Acad Sci USA* **103:**2257-2261.

Wang B, Love TM, Call ME, Doench JG, and Novina CD (2006) Recapitulation of short RNA-directed translational gene silencing in vitro. *Mol Cell* **22:**553-560.

Yamada H, Yanagisawa K, Tokumaru S, Taguchi A, Nimura Y, Osada H, Nagino M, and Takahashi T (2008) Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at 21q11-21 in human lung cancer. *Genes Chromosomes Cancer* **47:**810-818.

Molecular Pharmacology Fast Forward. Published on July 1, 2009 as DOI: 10.1124/mol.109.056986
This article has not been copyedited and formatted. The final version may differ from this version.



**Footnotes**

This work was supported in part by Research on Advanced Medical Technology, Health and Labor Science Research Grants from the Ministry of Health, Labor and Welfare of Japan (H20-BIO-G001) and Takeda Sciences Foundation.

Molecular Pharmacology Fast Forward. Published on July 1, 2009 as DOI: 10.1124/mol.109.056986
This article has not been copyedited and formatted. The final version may differ from this version.



**Figure legends**

Fig. 1. Predicted target sequence of miR-125b in the human CYP24 mRNA. The numbering refers to the ATG in translation starting with A as 1, and the coding region is up to +1,545. Sequence of MRE125b (gray box) is located on +1,575 to +1,592 in the 3'-UTR of human CYP24 mRNA. Bold letters represent seed sequence.

Fig. 2. Expression levels of miR-125b and CYP24 in various human cell lines. **A**, the expression levels of mature miR-125b in MCF-7, MDA-MB-435, KGN, HepG2, and HEK293 cells were determined by Northern blot analyses. **B**, the expression levels of mature miR-125b were determined by real-time RT-PCR. **C**, the expression levels of CYP24 protein were determined by Western blot analyses. **D**, the expression levels of CYP24 mRNA were determined by real-time RT-PCR. The expression levels were normalized with the expression level of GAPDH as a control. Values are expressed relative to the values in MCF-7 cells. Data are mean ± SD of triplicate determinations.

Fig. 3. Luciferase assays with reporter constructs containing MRE125b in human CYP24 in KGN and MCF-7 cells. A series of reporter constructs containing the 3'-UTR of the human CYP24 was transiently transfected into KGN cells with the AsO for miR-125b or control, or into MCF-7 cells with the precursors for miR-125b or control. The firefly luciferase activity for each construct was normalized with the *Renilla* luciferase activities. Values are expressed as percentages of the relative luciferase activity of pGL3-promoter plasmid. Each column represents the mean ± SD of three independent experiments. **, $P < 0.01$, compared with pGL3-promoter by ANOVA and Dunnett test. $^{\dagger}P < 0.05$, $^{\dagger\dagger}P < 0.01$, $\dagger\dagger\dagger P < 0.005$, compared with the control by student's *t*-test.

Fig. 4. Effects of miR-125b on the endogenous CYP24 protein level in KGN or MCF-7 cells. AsOs for miR-125b or control (2.5 pmol/4x$10^5$ cells) were transfected into KGN cells

Molecular Pharmacology Fast Forward. Published on July 1, 2009 as DOI: 10.1124/mol.109.056986
This article has not been copyedited and formatted. The final version may differ from this version.



and precursors for miR-125b or control (84 pmol/$1.68x10^5$ cells) were transfected into MCF-7 cells. After 72 hours, total RNA and whole-cell lysate were prepared. **A**, the expression levels of mature miR-125b were determined by Northern blot analysis. **B**, the expression levels of CYP24 protein were determined by Western blot analysis. **C**, the CYP24 enzymatic activity was determined using $25(OH)D_3$ as a substrate as described in Materials and Methods. Each column represents the mean ± SD of three independent experiments. $*P < 0.05$, $***P < 0.005$, compared with the control.

Fig. 5. Expression levels of CYP24 protein and miR-125b in human breast cancer tissues. **A**, immunohistochemical staining of CYP24 protein in breast cancer tissues. a, grade 2 invasive ductal carcinoma with normal IgG showed no staining. b, grade 2 invasive ductal carcinoma with anti-human CYP24 showed medium staining. c, grade 2 invasive ductal carcinoma with anti-human CYP24 showed high staining. B, the expression levels of mature miR-125b in breast cancer tissues and adjacent normal tissues obtained from 14 patients were determined by real-time RT-PCR. The expression levels were normalized with the 18S rRNA level. Horizontal and vertical bars represent the mean ± SD. **C**, the relationship between the CYP24 protein levels in breast cancer tissues and the cancer/normal ratio of mature miR-125b levels.


Human CYP24 mRNA
ATG
+1545
stop codon
+2889
Coding region
+1575
MRE125b
+1592
5'-cuaacaucaua---u-ccaacucagggaagcgga-3'
miR-125b
3'-aguguucaaucccagaguccc u-5'


A
Mature
miR-125b
B
Relative expression level
of mature miR-125b
35
30
25
20
15
10
5
0
MCF-7
MDA-
MB-435
KGN
HepG2
HEK293
C
CYP24
Relative expression level
of CYP24 protein
3
2
1
0
MCF-7
MDA-
MB-435
KGN
HepG2
HEK293
D
Relative expression level
of CYP24 mRNA
/GAPDH
35
30
25
20
15
10
5
0
MCF-7
MDA-
MB-435
KGN
HepG2
HEK293


Xba I
pGL3-promoter
Luc
poly(A)
pGL3/UTR1rev
+1609
+1529
pGL3/UTR1
pGL3/UTR2
pGL3/MRE3
pGL3/MRE3rev
pGL3/c-miR-125b
KGN
MCF-7
0
20
40
60
80
100
120
140
Relative luciferase activity
(Firefly/Renilla)
MRE125b
Perfect matching sequence for miR-125b
SV40 promoter
AsO for control
AsO for miR-125b
Precursor for control
Precursor for miR-125b


A
KGN
MCF-7
Mature miR-125b
Control
AsO for miR-125b
Control
Precursor for miR-125b
B
KGN
MCF-7
CYP24
β-Actin
CYP24 protein level /β-actin
2.0
1.5
1.0
0.5
0.0
***
*
Control
AsO for miR-125b
Control
Precursor for miR-125b
C
KGN
MCF-7
25(OH)D3 24-hydroxylase activity (pmol/min/mg)
1.5
1.0
0.5
0.0
*
Control
AsO for miR-125b
Control
Precursor for miR-125b

**A**

**a**. Grade 2 invasive ductal carcinoma stained with normal IgG



**b**. Grade 2 invasive ductal carcinoma showing moderate staining with anti-CYP24 antibodies



**c**. Grade 2 invasive ductal carcinoma showing strong staining with anti-CYP24 antibodies



**B**




**C**